Exact Mass: 674.2468318
Exact Mass Matches: 674.2468318
Found 154 metabolites which its exact mass value is equals to given mass value 674.2468318,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
(N-acetylneuraminosyl(a2-6)lactosamine)
(N-acetylneuraminosyl(alpha2-6)lactosamine) is widely distributed among tissues and is involved in biological processes such as the regulation of the immune response and the progression of colon cancer. Sialylation represents one of the most frequently occurring terminations of the oligosaccharide chains of glycoproteins and glycolipids. Sialic acid is commonly found alpha,6-linked to N-acetylgalactosamine (GalNAc). The biosynthesis of the linkage is mediated by a member of the sialyltransferase family, the beta-galactoside alpha,6-sialyltransferase (EC 2.4.99.1, ST6Gal.I). Although expressed by a single gene, this enzyme shows a complex pattern of regulation which allows its tissue- and stage-specific modulation. (PMID 11425186)
.6-Sialyllactosamine is an oligosaccharide found in human milk. Oligosaccharides in human milk inhibit enteric pathogens in vitro and in vivo. (PMID:10683228)
.(N-acetylneuraminosyl(alpha2-6)lactosamine) is widely distributed among tissues and is involved in biological processes such as the regulation of the immune response and the progression of colon cancer. Sialylation represents one of the most frequently occurring terminations of the oligosaccharide chains of glycoproteins and glycolipids. Sialic acid is commonly found alpha,6-linked to N-acetylgalactosamine (GalNAc). The biosynthesis of the linkage is mediated by a member of the sialyltransferase family, the beta-galactoside alpha,6-sialyltransferase (EC 2.4.99.1, ST6Gal.I). Although expressed by a single gene, this enzyme shows a complex pattern of regulation which allows its tissue- and stage-specific modulation. (PMID 11425186)
Premithramycin A2
A tetracenomycin that is an intermediate in the biosynthesis of the antitumour drug mithramycin by Streptomyces argillaceus.
3-Sialyl-N-acetyllactosamine
3-Sialyl-N-acetyllactosamine is a normal sialyloligosaccharide that is present in human biofluids, and is one of the predominant oligosaccharides in human urine as a free form. The presence of these compounds in the urine is linked to the biosynthesis and degradation of the body glycoproteins, glycolipids, and glycans. Under certain pathological conditions, the total urinary carbohydrate-material is increased dramatically, and the number and ratios of the components present are also increased. Many of these pathological disorders are the result of a deficiency in a specific exoglycosidase. 3-Sialyl-N-acetyllactosamine have a sialyl(a2-3) linkage and is of interest in view of the discovery of uropathogenic Escherichia coli strains with binding specificity for sialyl(a2-3)galactosides. (PMID: 2445744; 2775488; 3813552; 6619126; 6628386; 6628680; 6714239; 6746638; 7925342) [HMDB] 3-Sialyl-N-acetyllactosamine is a normal sialyloligosaccharide that is present in human biofluids, and is one of the predominant oligosaccharides in human urine as a free form. The presence of these compounds in the urine is linked to the biosynthesis and degradation of the body glycoproteins, glycolipids, and glycans. Under certain pathological conditions, the total urinary carbohydrate-material is increased dramatically, and the number and ratios of the components present are also increased. Many of these pathological disorders are the result of a deficiency in a specific exoglycosidase. 3-Sialyl-N-acetyllactosamine have a sialyl(a2-3) linkage and is of interest in view of the discovery of uropathogenic Escherichia coli strains with binding specificity for sialyl(a2-3)galactosides. (PMID: 2445744; 2775488; 3813552; 6619126; 6628386; 6628680; 6714239; 6746638; 7925342).
6-Sialyl-N-acetyllactosamine
6-Sialyl-N-acetyllactosamine is an oligosaccharide widely distributed among tissues and is involved in biological processes such as the regulation of the immune response and the progression of colon cancer. Sialylation represents one of the most frequently occurring terminations of the oligosaccharide chains of glycoproteins and glycolipids. Sialic acid is commonly found alpha,3- or alpha,6-linked to galactose (Gal), alpha,6-linked to N-acetylgalactosamine (GalNAc) or alpha,8-linked to another sialic acid. The biosynthesis of the various linkages is mediated by the different members of the sialyltransferase family. The b-galactoside a2,6 sialyltransferase (EC 2.4.99.1, ST6Gal.I) is the only sialyltransferase so far identified able to catalyze the a2,6-sialylation of lactosamine. Although expressed by a single gene, this enzyme shows a complex pattern of regulation which allows its tissue- and stage-specific modulation. The level of expression of the sialyl-alpha2,6-lactosaminyl structures and of ST6Gal.I show a strong dependence on neoplastic transformation and differentiation in several tissues. (PMID: 11425186) [HMDB] 6-Sialyl-N-acetyllactosamine is an oligosaccharide widely distributed among tissues and is involved in biological processes such as the regulation of the immune response and the progression of colon cancer. Sialylation represents one of the most frequently occurring terminations of the oligosaccharide chains of glycoproteins and glycolipids. Sialic acid is commonly found alpha,3- or alpha,6-linked to galactose (Gal), alpha,6-linked to N-acetylgalactosamine (GalNAc) or alpha,8-linked to another sialic acid. The biosynthesis of the various linkages is mediated by the different members of the sialyltransferase family. The b-galactoside a2,6 sialyltransferase (EC 2.4.99.1, ST6Gal.I) is the only sialyltransferase so far identified able to catalyze the a2,6-sialylation of lactosamine. Although expressed by a single gene, this enzyme shows a complex pattern of regulation which allows its tissue- and stage-specific modulation. The level of expression of the sialyl-alpha2,6-lactosaminyl structures and of ST6Gal.I show a strong dependence on neoplastic transformation and differentiation in several tissues. (PMID: 11425186).
3'-Sialyl-N-acetyllactosamine
Dirlotapide
Mucusisoflavone C
A hydroxyisoflavone, isoflavone dimer obtained from Ficus mucuso.
(+)-dihydrodehydrodiconiferyl alcohol 4-O-beta-(6-O-galloyl)-glucopyranoside
Boc-Gly-Pro-Hyp-Gly-Ala-Gly-OBzl-Antiarrhythmic peptide(ox atrium)
1-(4-hydroxy-3,5-dimethoxyphenyl)-2-{2,6-dimethoxy-4[(1E)-3-(4-hydroxybenzoyloxy)-1-propenyl]phenoxy}-3-(4-hydroxybenzoyloxy)propan-1-one|quiquelignan D
(-)-(7S,8R,8R)-9-O-galloyllariciresinol-4-O-beta-D-glucopyranoside|balaxiflorin A
(4alpha,5beta,10alpha,14alpha)-14,19-dihydroxyabieta-8,13(15)-dieno-16,12-lactone 19-(2-O-(4-hydroxy-3,5-dimethoxybenzoyl)-beta-D-glucopyranoside)|curvifloruside B|rel-(4R,4aS,7R,10aR,11bR)-2,3,4,4a,5,6,7,10a,11,11b-decahydro-7-hydroxy-4-({[2-O-(4-hydroxy-3,4-dimethoxybenzoyl)-beta-D-glucopyranosyl]oxy}methyl)-4,8,11b-trimethylphenanthro[3,2-b]furan-9(1H)-one
6alpha,12-diacetoxy-2beta,9alpha-di(beta-furancarbonyloxy)-4alpha-hydroxy-1beta-(2-methylbutanoyloxy)-beta-dihydroagarofuran
(-)-secoisolariciresinol 4-O-beta-D-(6-O-vanilloyl)glucopyranoside|glehlinoside A
C34H42O14_(1S,2S,4S,5R,6R,7S,9R,12R)-12-Acetoxy-6-(acetoxymethyl)-2-hydroxy-2,10,10-trimethyl-5-[(2-methylbutanoyl)oxy]-11-oxatricyclo[7.2.1.0~1,6~]dodecane-4,7-diyl di(3-furoate)
Biflavonoid-flavone base + 3MeO and flavone base + 3MeO
Annotation level-3
Phe His Trp Trp
Phe Trp His Trp
Phe Trp Trp His
His Phe Trp Trp
His Trp Phe Trp
His Trp Trp Phe
Trp Phe His Trp
Trp Phe Trp His
Trp His Phe Trp
Trp His Trp Phe
Trp Trp Phe His
Trp Trp His Phe
3-SLN
NeuAc alpha,6gal beta1,4gicnac
5,10,15,20-TETRAKIS(4-AMINOPHENYL)-21H,23H-PORPHINE
[1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidene](1,3-diphenyl-1,3-propanedionato)copper(I)
C42H47CuN2O2 (674.2933332000001)
O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-2-(acetylamino)-2-deoxy-D-galactose
1-[(2R,3R)-2-[[2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-(1-naphthalenyl)urea
C35H38N4O8S (674.2410228000001)
beta-D-galactosyl-(1->3)-[alpha-N-acetylneuraminosyl-(2->6)]-N-acetyl-alpha-D-galactosamine
alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc
alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-alpha-D-GalpNAc
beta-NeupNAc-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc
2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1->4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)]-beta-D-galactopyranose
locoracemoside C
An O-acyl carbohydrate consisting of 6-O-beta-D-glucopyranosyl-beta-D-glucopyranose attached to a 3,4,5-trimethoxybenzyl and a galloyl group at positions 1 and 3 respectively. Isolated from Symplocos racemosa, it exhibits inhibitory activity against chymotrypsin.
beta-D-Galp-(1->3)-[beta-Neup5Ac-(2->6)]-alpha-D-GalpNAc
2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1->4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)]-D-galactopyranose
5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2->3)-D-galacto-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranose
D-galacto-hexopyranosyl-(1->3)-[5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->6)]-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranose
[(1S,4R,6E,9R,12R,13S,15R,16R)-4,9-dibenzyl-15-(hydroxymethyl)-13-methoxy-3,10-dioxo-2,11,14-trioxabicyclo[10.4.0]hexadec-6-en-16-yl] 2,6-dimethoxybenzoate
5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-beta-D-galacto-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-D-galacto-hexopyranose
3-O-[3-O-[(N-Acetyl-2-deoxy-alpha-neuraminic acid)-2-yl]-D-galactopyranosyl]-2-(acetylamino)-2-deoxy-D-galactopyranose
D-galacto-hexopyranosyl-(1->3)-[5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->6)]-2-acetamido-2-deoxy-D-galacto-hexopyranose
5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-beta-D-galacto-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranose
5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2->3)-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-hexopyranose
(2beta,3alpha,5alpha,6alpha)-ergostane-2,3,6-triyl tris(hydrogen sulfate)
Halistanol sulfonic acid G
A steroid sulfate that is 5alpha-ergostane substituted by sulfate groups at positions 2, 3 and 6 (the (2beta,3alpha,6alpha stereoisomer).
(7r)-7-[(1z)-2-(1,5-dihydroxy-3-methoxy-10-methyl-9-oxoacridin-4-yl)ethenyl]-15-hydroxy-2,7,19,19-tetramethyl-5,8,18-trioxa-2-azapentacyclo[12.8.0.0³,¹².0⁴,⁹.0¹⁷,²²]docosa-1(22),3,9,11,14,16,20-heptaen-13-one
(2s,4s,5r,6r)-6-[(1r,2r)-2,3-dihydroxy-1-{[(2s,3r,4r,5s,6r)-5-hydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}propyl]-2,4-dihydroxy-5-[(1-hydroxyethylidene)amino]oxane-2-carboxylic acid
4,4',5,5'-tetrahydroxy-2,2'-dimethoxy-7,7'-dimethyl-3,3'-bis[(1e)-3-methylbut-1-en-1-yl]-9h,9'h-[9,9'-bianthracene]-10,10'-dione
7-[2-(1,5-dihydroxy-3-methoxy-10-methyl-9-oxoacridin-4-yl)ethenyl]-15-hydroxy-2,7,19,19-tetramethyl-5,8,18-trioxa-2-azapentacyclo[12.8.0.0³,¹².0⁴,⁹.0¹⁷,²²]docosa-1(22),3,9,11,14,16,20-heptaen-13-one
(1s,2s,4s,5r,6r,7s,9r,12r)-12-(acetyloxy)-6-[(acetyloxy)methyl]-7-(furan-3-carbonyloxy)-2-hydroxy-2,10,10-trimethyl-5-{[(2r)-2-methylbutanoyl]oxy}-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-4-yl furan-3-carboxylate
7-[(1e)-2-(1,5-dihydroxy-3-methoxy-10-methyl-9-oxoacridin-4-yl)ethenyl]-15-hydroxy-2,7,19,19-tetramethyl-6,8,18-trioxa-2-azapentacyclo[12.8.0.0³,¹².0⁴,⁹.0¹⁷,²²]docosa-1(22),3,9,11,14,16,20-heptaen-13-one
(3s,6r,10r,13e,16s)-10-[(3,5-dichloro-4-hydroxyphenyl)methyl]-9,12-dihydroxy-6-methyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadeca-8,11,13-triene-2,5-dione
C34H40Cl2N2O8 (674.2161580000002)